Consistently, KDM4A inhibition with the combination of anti-PD-1 antibody treatment suppresses tumor growth and metastasis [123], suggesting that epigenetic modification of STING signaling mediated by KDM4A histone demethylation might positively drive anti-tumor immunity. The gene discussed is KDM4A; the disease is neoplasm.